Effect of Helicobacter pylori infection on the course of nonalcoholic fatty liver disease

Лазебник, Л. Б.; Тарасова, Л. В.; Komarova, Elena A.; Бусалаева, Е. И.

doi:10.31146/1682-8658-ecg-172-12-90-94

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Развитие НАЖБП связано с ожирением, СД 2 типа и МС. В последнее время появились клинические и экспериментальные данные об участии в ее патогенезе микробиоты желудочно-кишечного тракта, в том числе инфекции H. py lo ri [21][22][23].…”

Section: неалкогольная жировая болезнь печениunclassified

The role of <i>Helicobacter pylori</i> in metabolic and cardiovascular diseases

Куглер

Тарадин

Pellicano

2021

jour

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) infection is one of the most common in the world. More than 50% of the world’s population is infected and infection rates are especially high in countries with poor socio-economic conditions. H. pylori causes gastroduodenal and extra-gastroduodenal diseases including such metabolic disorders as obesity, diabetes mellitus and non-alcoholic fatty liver disease. Recent epidemiological and clinical studies showed that the long-term persistence of H. pylori infection is associated with the development and progression of atherosclerosis and consequently cardiovascular diseases. However, the correlation between these conditions is ambiguous and there is not enough evidence to confirm it. The lack of consensus might be related to differences in diagnostic methods used for H. pylori and the variety of its genotypes. Considering high prevalence of H. pylori infection as well as high incidence of metabolic and cardiovascular diseases, a verified correlation between these can be of great epidemiological, prophylactic and clinical significance.

show abstract

Section: неалкогольная жировая болезнь печениunclassified

The role of <i>Helicobacter pylori</i> in metabolic and cardiovascular diseases

Куглер

Тарадин

Pellicano

2021

jour

View full text Add to dashboard Cite

show abstract

“…Неалкогольная жировая болезнь печени (НАЖБП) в современную эпоху является серьезной медицинской проблемой и представляет одну из наиболее признанных причин патологии печени в современном мире [1,2]. Согласно результатам российского исследования DIREG 1 (2007 г), заболеваемость НАЖБП насчитывала 27% [3].…”

Section: Introductionunclassified

Hyperammonemia in patients with stable angina pectoris and nonalcoholic fatty liver disease at the steatosis stage

Zykina,

Simonova

2023

jour

View full text Add to dashboard Cite

The aim. To assess the severity of hyperammoniemia in patients with non-alcoholic fatty liver disease at the steatosis stage in conditions of comorbidity with stable angina. Research materials and methods. During the clinical trial, three groups of patients with stable angina were formed. Group I (n = 43) consisted of patients with NAFLD at the stage of hepatic steatosis in combination with obesity and a stable form of CHD. Group II (n = 41) - patients with NAFLD at the stage of hepatic steatosis against the background of normal body weight and stable CHD. Group III (control) (n = 42) - patients with stable angina without NAFLD, with normal body weight. The results of laboratory examination (clinical and biochemical blood tests, lipidograms, insulin levels (calculated by HOMA-IR), glycosylated hemoglobin (HbAlc)) were evaluated; non-invasive markers for the diagnosis of liver injury. Hyperammonemia was evaluated by quantitative rapid ammonia analysis using a Pocket Chem TM BA PA-4140 analyzer. All patients underwent ultrasound of the liver using Philips Epiq 5 (USA). Results. In all patients with stable angina (group I and II), the diagnosis of non-alcoholic fatty liver disease, steatosis stage, was confirmed. The lipid profile of patients in Groups I and II showed more significant hypertriglyceridemia compared to those in the control group, with no statistical difference in Groups I and II. The mean ammonium level in patients with NAFLD in combination with stable CHD (group I, II) was above the threshold and was 87 (57-127.5) and 79 (57-97) μmol/L, respectively, and did not differ significantly (p > 0.05). In patients of group III (without liver disease), the mean values of ammonia in the blood were in the target range. According to the results of correlation analysis, we established the relationship of ammonium with liver enzymes, calculated steatosis indices and basic metabolic indicators. Conclusion. Patients with non-alcoholic fatty liver disease in the steatosis stage with a combination of stable angina have more severe hyperammonemia compared to patients with stable CHD without concomitant liver injury.

show abstract

Effect of Helicobacter pylori infection on the course of nonalcoholic fatty liver disease

Cited by 2 publications

References 11 publications

The role of <i>Helicobacter pylori</i> in metabolic and cardiovascular diseases

The role of <i>Helicobacter pylori</i> in metabolic and cardiovascular diseases

Hyperammonemia in patients with stable angina pectoris and nonalcoholic fatty liver disease at the steatosis stage

Contact Info

Product

Resources

About